We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Triple-negative Breast Cancers Can Adopt Reversible State That is Resistant to Chemotherapy

News   Apr 23, 2019 | Original story from The University of Texas MD Anderson Cancer Center

 
Triple-negative Breast Cancers Can Adopt Reversible State That is Resistant to Chemotherapy

This image shows a triple-negative breast cancer cell (MDA-MB-231) in metaphase during cell division. Tubulin in red; mitochondria in green; chromosomes in blue. A better understanding of how mitochondria play roles in tumor cell division may provide new therapeutic targeting strategies to stop tumor cell growth. Credit: National Cancer Institute \ Univ. of Pittsburgh Cancer Institute. Creator: Wei Qian

 
 
 

RELATED ARTICLES

Revival of 50,000-Year-Old Gene Reveals How Deadliest Malaria Parasite Jumped from Gorillas to Humans

News

In a study published today in PLOS Biology, researchers from the Wellcome Sanger Institute and the University of Montpellier have reconstructed a ~50,000-year-old gene sequence acquired by the ancestor of Plasmodium falciparum. The acquisition of the gene sequence enabled the parasite to infect human red blood cells.

READ MORE

New Centers Aim To Drive Green Chemistry Innovation

News

Monash University has received $8.6 million in Federal Government funding to establish dedicated research training centers that are set to drive the innovation of green chemistry in Australian manufacturing.

READ MORE

Fungus Chemistry May Mimic Opioids With Fewer Side Effects

News

The hunt for an opioid alternative has made a leap forward – a unique fungus may be able to mimic opioid suggesting it could be a safer less addictive drug, helping address the opioid epidemic of deaths by overdose.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE